Post Reply
221-240 of 1176
Did you guess this infor yourself or you get it from somewhere?
Cadence88 ( Date: 01-Aug-2024 15:09) Posted:
|
Yes, long time no see. Nice to see u here.
80cts...ya...seem like yesterday.
Ok, we wait together.
That time play with u together from 0.7x till 1.xx.
Ee...time flies.
May u have a great day/
80cts...ya...seem like yesterday.
Ok, we wait together.
That time play with u together from 0.7x till 1.xx.
Ee...time flies.
May u have a great day/
halleluyah ( Date: 01-Aug-2024 10:29) Posted:
|
the trading window for senior mgmt may not have opened yet
Secret_Squirrel ( Date: 01-Aug-2024 10:41) Posted:
|
The power of market can not be reversed by indivviduals.
Secret_Squirrel ( Date: 01-Aug-2024 10:41) Posted:
|
At share price of 94 cents, Dr Loo has made a paper loss of more than $2.7 million from his purchases between Feb to Jun 2024. lol
No wonder did not see him make any purchase after the release of the result. lol
Let' s see this evening whether there is any fileing of his purchase at SGX website.
No wonder did not see him make any purchase after the release of the result. lol
Let' s see this evening whether there is any fileing of his purchase at SGX website.
halleluyah ( Date: 01-Aug-2024 10:29) Posted:
|
hi bro lucky, long time no see...am waitng fr 80ct n blw as dun wt to b a bag holder like b4...results looks so bad...
SuperLuckyCorn ( Date: 01-Aug-2024 10:17) Posted:
|
Yes, in mid term good.
In short term, watch carefully, enter at gradually.
Then can squeeze dry the shortists more easily.
Nevertheless, trade with care.
In short term, watch carefully, enter at gradually.
Then can squeeze dry the shortists more easily.
Nevertheless, trade with care.
Mark001 ( Date: 31-Jul-2024 16:10) Posted:
|
When the price drops,why does Dr. Loo keep buying back since he should have a good idea of how the company will perform this year?
Mark001 ( Date: 31-Jul-2024 16:10) Posted:
|
There is still room for decline in the short term but it is stable in long term.
It will take TIME to make bussiness grow instead of share backback.
You have to bear your own responsibilty.
It will take TIME to make bussiness grow instead of share backback.
You have to bear your own responsibilty.
HuatAh7898 ( Date: 31-Jul-2024 15:07) Posted:
|
Heavy selling pressures all over ...
Why ah
Trade with strong awareness
Why ah
Trade with strong awareness
Analysts cut Raffles Medical earnings estimates after results miss
The group attributes its decline in net profit to the cessation of Covid-19 activities and government grants, as well as higher insurance service costs
ANALYSTS have cut their earnings estimates for Raffles Medical after the company released lower-than-expected earnings for the first half ended Jun 30.
RHB lowered its target price to S$1 from S$1.06. It had cut FY2024 to FY2026 earnings estimates by 11 to 13 per cent.
Maybank Securities also trimmed its target to S$1.10 from S$1.15. Analyst Eric Ong reduced his FY2024 to FY2025 earnings per share forecasts by 7 to 9 per cent.
Meanwhile, DBS Group Research maintained its target price of S$0.97, but shaved its estimates for FY2024 earnings by 8 per cent and FY2025 by 3 per cent.
On Monday (Jul 29), Raffles Medical posted a 48.8 per cent decline in net profit to S$30.6 million for the first half, mainly due to the cessation of Covid-19 activities and government grants, as well as higher insurance service costs.
RHB analyst Shekhar Jaiswal said while longer-term growth remains driven by the group&rsquo s overseas operations, he expects limited re-rating catalysts in the near term.
&ldquo Instead, we note potential earnings headwinds from higher operating costs, lower numbers of foreign patients, and sustained losses in its insurance business,&rdquo he said in a report on Tuesday.
Similarly, Maybank&rsquo s Ong believes that growth in Raffles Medical&rsquo s insurance unit remains challenging, given industry trends of higher claims and loss ratio.
That said, both Ong and Jaiswal remain positive on the group&rsquo s hospital services. Both brokerages kept their &ldquo hold&rdquo and &ldquo neutral&rdquo calls on the counter.
Highlighting that the segment is Raffles Medical&rsquo s &ldquo only bright spot&rdquo , Ong believes rising demand from local and foreign patients could offset declines in earnings per share.
&ldquo Balance sheet is strong with a net cash position, which enables the group to maintain its core payout ratio of 50 per cent,&rdquo he added, noting that capital expenditures may decrease after its Shanghai hospital is developed.
Jaiswal also projects higher revenue in the segment, led by Chinese hospital operations. He expects their earnings before interest, tax, depreciation and amortisation to break even by end 2025 at the earliest.
While DBS analysts Amanda Tan and Andy Sim said China hospitals are a &ldquo promising growth engine&rdquo , they remain cautious about losses incurred during their development and launch phases.
&ldquo China&rsquo s slowing economic growth and the stronger Singapore dollar may also dampen the demand for high-end healthcare services, while margins may face some compression due to inflationary pressures,&rdquo they said.
However, the analysts also expect full-year earnings to normalise in the current fiscal year. &ldquo This could cap the share price&rsquo s upward momentum,&rdquo they added.
They are also sanguine on Raffles Medical&rsquo s long-term outlook due to the industry&rsquo s long-term positive trajectory. As a result, DBS analysts also maintained their &ldquo hold&rdquo call on the stock.
China operation is losing big .
no dividend for shareholders...
Trade with expectations
Trade with expectations
Dr Loo would probably buy to average down, but his purchases unlikely to push up price.
The volume of shares transacted as of now is about 11,138, 400 shares
The volume of shares transacted as of now is about 11,138, 400 shares
Mark001 ( Date: 30-Jul-2024 14:41) Posted:
|
Dr. Loo will not buyback share even he can do.
I guess.
I guess.
Secret_Squirrel ( Date: 17-Jul-2024 11:08) Posted:
|
wait for a better potential point.
kiseki_2818 ( Date: 30-Jul-2024 11:09) Posted:
|
good potential
Joelton ( Date: 29-Jul-2024 10:14) Posted:
|
跳 楼 ， ， 跳 楼 ， ，
Raffles Medical Group&rsquo s 1HFY2024 patmi down 48.8% y-o-y on cessation of Covid-19 activities
Raffles Medical Group has posted a 1HFY2024 ended June patmi of $30.6 million, down 48.8% y-o-y compared to the previous corresponding period.
Revenue was also down by 1.4% y-o-y to $365.7 million. The lower revenue and patmi was due to the cessation of Covid-19 activities, which discontinued progressively in 1H2023.
Earnings per share for 1HFY2024 stood at 1.62 cents, 49.4% lower than the 3.20 cents recorded in 1HFY2023.
The company&rsquo s core hospital services division registered a revenue of $167.6 million and profit of $14.3 million. This was 4.5% and 65% higher y-o-y respectively, with improved operating leverages.
Its healthcare services division registered lower revenue and profitability of $141.3 million and $27.6 million respectively in 1H 2024 after the cessation of COVID-19 services.
Raffles Health Insurance&rsquo s (RHI) revenue grew by 28.9% to $86.2 million for 1HFY2024. Consistent with industry trends, RHI experienced higher claims and registered a higher loss ratio during the period. Operating loss was $6.4 million as compared to $1.3 million that was reported in 1HFY2023.
Raffles Medical&rsquo s balance sheet stood at $316.3 million in cash and cash equivalents as at June 30.
MEDIA RELEASE
RafflesMedicalGroup Reports Profit After Tax of
S$30.9 million in 1H 2024
Singapore, 29 July 2024 ? RafflesMedicalGroup (the Group) posted a revenue of S$365.7
million, and Profit after tax and minority interests (PATMI) of S$30.6 million. Revenue and PATMI for
1H 2024 was lower than 1H 2023 by 1.4% and 48.8%, respectively, due to the cessation of COVID-19
activities which discontinued progressively in 1H 2023.
The Group?s core Hospital Services division remained strong and profitable, registering a revenue of
S$167.6 million and profit of S$14.3 million. Compared to 1H 2023, Hospital Services revenue for 1H
2024 grew 4.5% and profit grew 65.0% with improved operating leverages. Although, the Raffles
Hospitals in China are gaining traction with growing patient number, our hospitals in Shanghai and
Chongqing are still in the developmental phase and continued to incur gestational losses.
The Group?s Healthcare Services division registered lower revenue and profitability of S$141.3 million
and S$27.6 million respectively in 1H 2024 after the cessation of COVID-19 services.
RafflesHealthinsurance?s (RHI) revenue grew by 28.9% to S$86.2 million for 1H 2024.
Consistent with industry trends, RHI experienced higher claims, and registered a higher loss ratio
in 1H 2024. Operating loss was S$6.4 million as compared to S$1.3 million that was reported in
1H 2023.
The Group?s balance sheet remained strong with S$316.3 million in cash and cash equivalents as at
30 June 2024.....
https://links.sgx.com/1.0.0/corporate-announcements/BLIIUGAQ1MSV2MC4/813186_RafflesMedicalGroup_Media_Release_1H2024_Result_Announcement_29Jul2024.pdf